Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Ibrutinib produces high response rates and durable remissions in Waldenström macroglobulinemia (WM) that are impacted by MYD88 and CXCR4(WHIM) mutations. Disease progression can develop on ibrutinib, although the molecular basis remains to be clarified. We sequenced sorted CD19(+) lymphoplasmacytic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Xu, Lian, Tsakmaklis, Nicholas, Yang, Guang, Chen, Jiaji G., Liu, Xia, Demos, Maria, Kofides, Amanda, Patterson, Christopher J., Meid, Kirsten, Gustine, Joshua, Dubeau, Toni, Palomba, M. Lia, Advani, Ranjana, Castillo, Jorge J., Furman, Richard R., Hunter, Zachary R., Treon, Steven P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484977/
https://ncbi.nlm.nih.gov/pubmed/28235842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-01-761726
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars